Adverse Event Management in Patients with
Adenocarcinoma of Lung
/ drug therapy
Adrenal Cortex Hormones
/ therapeutic use
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cohort Studies
Disease Management
Drug-Related Side Effects and Adverse Reactions
/ drug therapy
Female
Follow-Up Studies
Humans
Imidazoles
/ administration & dosage
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Oximes
/ administration & dosage
Prognosis
Proto-Oncogene Proteins B-raf
/ genetics
Pyridones
/ administration & dosage
Pyrimidinones
/ administration & dosage
Survival Rate
BRAF
Cutaneous events
Non‐small cell lung cancer
Pyrexia
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
16
05
2018
accepted:
15
11
2018
pubmed:
2
1
2019
medline:
10
7
2020
entrez:
2
1
2019
Statut:
ppublish
Résumé
Therapies for advanced non-small cell lung cancer (NSCLC) continue to become more sophisticated. Chemotherapeutics are giving way to newer approaches such as immune checkpoint inhibitors and targeted therapies for greater efficacy and improved outcomes. Dabrafenib plus trametinib combination therapy was first approved for the treatment of metastatic melanoma harboring the
Identifiants
pubmed: 30598499
pii: theoncologist.2018-0296
doi: 10.1634/theoncologist.2018-0296
pmc: PMC6656467
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Imidazoles
0
Oximes
0
Pyridones
0
Pyrimidinones
0
trametinib
33E86K87QN
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
dabrafenib
QGP4HA4G1B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
963-972Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Cancer Cell. 2002 Jul;2(1):5-7
pubmed: 12150818
Cancer Res. 2002 Dec 1;62(23):6997-7000
pubmed: 12460918
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
J Surg Res. 2006 Jun 15;133(2):203-6
pubmed: 16376942
Int J Cancer. 2006 Oct 15;119(8):1858-62
pubmed: 16721785
Biochim Biophys Acta. 2007 Aug;1773(8):1248-55
pubmed: 17194493
Oncologist. 2008 Sep;13(9):1001-11
pubmed: 18779536
Appl Immunohistochem Mol Morphol. 2009 Mar;17(2):121-5
pubmed: 18987552
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Clin Oncol. 2011 May 20;29(15):2046-51
pubmed: 21483012
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
J Clin Oncol. 2011 Sep 10;29(26):3574-9
pubmed: 21825258
Anticancer Res. 2011 Dec;31(12):4619-23
pubmed: 22199339
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Lancet Oncol. 2012 Aug;13(8):782-9
pubmed: 22805292
Oncol Lett. 2010 Jul;1(4):729-732
pubmed: 22966370
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Cancer Treat Rev. 2013 Oct;39(6):664-72
pubmed: 23434072
Oncologist. 2013;18(3):314-22
pubmed: 23457002
Curr Oncol Rep. 2013 Jun;15(3):249-59
pubmed: 23463215
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Clin Cancer Res. 2013 Aug 15;19(16):4532-40
pubmed: 23833300
Ann Oncol. 2014 Jan;25(1):138-42
pubmed: 24297085
Australas J Dermatol. 2014 Nov;55(4):250-4
pubmed: 24313958
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Ann Oncol. 2014 Jul;25(7):1437-41
pubmed: 24864047
PLoS One. 2014 Jun 30;9(6):e101354
pubmed: 24979348
Melanoma Res. 2014 Oct;24(5):468-74
pubmed: 25054915
Semin Oncol Nurs. 2014 Aug;30(3):155-68
pubmed: 25085027
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Cancer. 2015 Feb 1;121(3):448-56
pubmed: 25273224
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Ann Oncol. 2015 Feb;26(2):415-21
pubmed: 25411413
J Thorac Oncol. 2014 Nov;9(11):1669-74
pubmed: 25436800
Ther Adv Drug Saf. 2015 Feb;6(1):4-14
pubmed: 25642318
Ther Adv Med Oncol. 2015 Mar;7(2):122-36
pubmed: 25755684
Chin Clin Oncol. 2014 Sep;3(3):29
pubmed: 25841455
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
J Thorac Oncol. 2015 Oct;10(10):1396-403
pubmed: 26301799
Lung Cancer. 2016 Jan;91:23-8
pubmed: 26711930
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Lancet Oncol. 2016 May;17(5):642-50
pubmed: 27080216
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
J Pathol Transl Med. 2017 May;51(3):242-254
pubmed: 28427247
Oncologist. 2017 Jul;22(7):786-796
pubmed: 28487464
Oncologist. 2017 Jul;22(7):823-833
pubmed: 28526719
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949